Antipsychotic medication use by Medicaid recipients with severe mental illness

Bentson McFarland, T. Scott Stroup, Aileen B. Rothbard, Mary Rose Murrin, Paul G. Stiles, David L. Shern, Roger A. Boothroyd, Elizabeth I. Merwin, Joseph P. Morrissey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Data on Medicaid recipients with severe mental illness were studied to determine antipsychotic medication use and any trends in racial variation in the prescribing of newer antipsychotic drugs. The study was conducted in 3 states. Participants were interviewed at entry into the study and again 6 months later. Interview data were linked with Medicaid eligibility information and claims data that included pharmacy records. Antipsychotic drugs, not infrequently in combination, are often prescribed for Medicaid recipients with severe mental illness. Medication use patterns tended to persist over the study period. No racial disparity with regard to use of newer antipsychotic medications was found. Further work is needed to understand psychotropic medication use by Medicaid recipients and to facilitate conformance with best-practice guidelines for treatment of persons with severe mental illness.

Original languageEnglish (US)
Pages (from-to)204-224
Number of pages21
JournalDrug Benefit Trends
Volume16
Issue number4
StatePublished - Apr 2004

Fingerprint

Medicaid
Antipsychotic Agents
Practice Guidelines
Interviews

Keywords

  • Antipsychotic medications
  • Medicaid
  • Polypharmacy
  • Prescribing, race disparity

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

McFarland, B., Stroup, T. S., Rothbard, A. B., Murrin, M. R., Stiles, P. G., Shern, D. L., ... Morrissey, J. P. (2004). Antipsychotic medication use by Medicaid recipients with severe mental illness. Drug Benefit Trends, 16(4), 204-224.

Antipsychotic medication use by Medicaid recipients with severe mental illness. / McFarland, Bentson; Stroup, T. Scott; Rothbard, Aileen B.; Murrin, Mary Rose; Stiles, Paul G.; Shern, David L.; Boothroyd, Roger A.; Merwin, Elizabeth I.; Morrissey, Joseph P.

In: Drug Benefit Trends, Vol. 16, No. 4, 04.2004, p. 204-224.

Research output: Contribution to journalArticle

McFarland, B, Stroup, TS, Rothbard, AB, Murrin, MR, Stiles, PG, Shern, DL, Boothroyd, RA, Merwin, EI & Morrissey, JP 2004, 'Antipsychotic medication use by Medicaid recipients with severe mental illness', Drug Benefit Trends, vol. 16, no. 4, pp. 204-224.
McFarland B, Stroup TS, Rothbard AB, Murrin MR, Stiles PG, Shern DL et al. Antipsychotic medication use by Medicaid recipients with severe mental illness. Drug Benefit Trends. 2004 Apr;16(4):204-224.
McFarland, Bentson ; Stroup, T. Scott ; Rothbard, Aileen B. ; Murrin, Mary Rose ; Stiles, Paul G. ; Shern, David L. ; Boothroyd, Roger A. ; Merwin, Elizabeth I. ; Morrissey, Joseph P. / Antipsychotic medication use by Medicaid recipients with severe mental illness. In: Drug Benefit Trends. 2004 ; Vol. 16, No. 4. pp. 204-224.
@article{64dbfee5deb8417fbce552a780af1b21,
title = "Antipsychotic medication use by Medicaid recipients with severe mental illness",
abstract = "Data on Medicaid recipients with severe mental illness were studied to determine antipsychotic medication use and any trends in racial variation in the prescribing of newer antipsychotic drugs. The study was conducted in 3 states. Participants were interviewed at entry into the study and again 6 months later. Interview data were linked with Medicaid eligibility information and claims data that included pharmacy records. Antipsychotic drugs, not infrequently in combination, are often prescribed for Medicaid recipients with severe mental illness. Medication use patterns tended to persist over the study period. No racial disparity with regard to use of newer antipsychotic medications was found. Further work is needed to understand psychotropic medication use by Medicaid recipients and to facilitate conformance with best-practice guidelines for treatment of persons with severe mental illness.",
keywords = "Antipsychotic medications, Medicaid, Polypharmacy, Prescribing, race disparity",
author = "Bentson McFarland and Stroup, {T. Scott} and Rothbard, {Aileen B.} and Murrin, {Mary Rose} and Stiles, {Paul G.} and Shern, {David L.} and Boothroyd, {Roger A.} and Merwin, {Elizabeth I.} and Morrissey, {Joseph P.}",
year = "2004",
month = "4",
language = "English (US)",
volume = "16",
pages = "204--224",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "4",

}

TY - JOUR

T1 - Antipsychotic medication use by Medicaid recipients with severe mental illness

AU - McFarland, Bentson

AU - Stroup, T. Scott

AU - Rothbard, Aileen B.

AU - Murrin, Mary Rose

AU - Stiles, Paul G.

AU - Shern, David L.

AU - Boothroyd, Roger A.

AU - Merwin, Elizabeth I.

AU - Morrissey, Joseph P.

PY - 2004/4

Y1 - 2004/4

N2 - Data on Medicaid recipients with severe mental illness were studied to determine antipsychotic medication use and any trends in racial variation in the prescribing of newer antipsychotic drugs. The study was conducted in 3 states. Participants were interviewed at entry into the study and again 6 months later. Interview data were linked with Medicaid eligibility information and claims data that included pharmacy records. Antipsychotic drugs, not infrequently in combination, are often prescribed for Medicaid recipients with severe mental illness. Medication use patterns tended to persist over the study period. No racial disparity with regard to use of newer antipsychotic medications was found. Further work is needed to understand psychotropic medication use by Medicaid recipients and to facilitate conformance with best-practice guidelines for treatment of persons with severe mental illness.

AB - Data on Medicaid recipients with severe mental illness were studied to determine antipsychotic medication use and any trends in racial variation in the prescribing of newer antipsychotic drugs. The study was conducted in 3 states. Participants were interviewed at entry into the study and again 6 months later. Interview data were linked with Medicaid eligibility information and claims data that included pharmacy records. Antipsychotic drugs, not infrequently in combination, are often prescribed for Medicaid recipients with severe mental illness. Medication use patterns tended to persist over the study period. No racial disparity with regard to use of newer antipsychotic medications was found. Further work is needed to understand psychotropic medication use by Medicaid recipients and to facilitate conformance with best-practice guidelines for treatment of persons with severe mental illness.

KW - Antipsychotic medications

KW - Medicaid

KW - Polypharmacy

KW - Prescribing, race disparity

UR - http://www.scopus.com/inward/record.url?scp=2142660807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142660807&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:2142660807

VL - 16

SP - 204

EP - 224

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - 4

ER -